financetom
Business
financetom
/
Business
/
Progressive's November Surge: EPS Soars 49% As Premiums Hit $6 Billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Progressive's November Surge: EPS Soars 49% As Premiums Hit $6 Billion
Dec 13, 2024 8:01 AM

Progressive Corporation ( PGR ) saw a positive trading day on Friday, buoyed by strong November performance.

The company reported an earnings per share of $1.71, a significant increase from $1.15 in the same month last year. Net premiums written for the month totaled $5.563 billion, marking an 18% year-over-year increase.

Additionally, net premiums earned rose 19% to $6.04 billion, while net income jumped by 48%, highlighting Progressive’s strong financial growth.

Also Read: Hershey Merger Talks Melt: Did High Cocoa Prices, Mondelez Buyback Program Hurt Deal?

In addition to solid financial results, Progressive last month announced the launch of its new safety feature, Accident Response, aimed at enhancing customer peace of mind.

This feature, which is available nationwide, is particularly relevant as the winter season approaches, bringing with it an increased risk of accidents due to icy and snowy conditions.

According to the Federal Highway Administration, nearly 70% of U.S. roads are in areas prone to snowy conditions, contributing to over 116,000 annual vehicle crashes on slippery roads.

Accident Response uses phone sensors to detect significant accidents and promptly notifies the driver. If a crash is detected, Progressive reaches out to offer assistance, and if the driver is unresponsive, emergency services are dispatched. Additionally, the app allows customers to quickly request emergency services or a tow, with Progressive automatically submitting a claim on their behalf.

Price Action: PGR shares are trading higher by 3.96% to $252.37 at last check Friday.

Read Next: 

SoFi Unlocks SpaceX Exposure For Retail Investors: Here's How

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved